Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT ID: NCT04210843

Last Updated: 2024-06-20

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 1033 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-08
• Study Completion Date: 2022-09-01

Brief Summary

The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1-antihistamine (H1-AH) treatment.

This study also fulfilled the Novartis commitment to provide post-trial access to patients who had completed studies: CQGE031C2302 (NCT03580369), CQGE031C2303 (NCT03580356), CQGE031C2202 (NCT03437278) or CQGE031C1301 (NCT03907878).

Detailed Description

This was a Phase IIIb multi-center, double-blinded and open-label extension study to evaluate efficacy and safety of ligelizumab retreatment with H1-AHs background therapy with an option for ligelizumab monotherapy (i.e., discontinuation of background H1-AH) in adult and adolescent CSU participants who had completed one of the preceding studies, in the setting of retreatment and self-administration.

Participants with weekly urticaria activity score (UAS7) < 16 during screening entered the first (investigational treatment-free) observation period (OBS1), with a duration up to 36 weeks.

Participants with UAS7 ≥ 16 during screening or OBS1 were assigned to 1 of the 2 treatment arms and entered the treatment period (first half treatment period, referred to as TRT1). The first half treatment period (TRT1) was 52 weeks (from Week 0 to Week 52). Participants remained on the same H1-AH background medication they were taking in the preceding studies. TRT1 was divided into:

• The first 12 weeks in TRT1:

i. participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg liquid in vial subcutaneously (s.c.) every 4 weeks (Q4W) were treated with the same dose regimen in a double-blind manner in this extension study; ii. all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg liquid in vial s.c., Q4W, in a double-blind manner in this extension study; iii. participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg liquid in vial s.c., Q4W in an open-label manner in this extension study.

• After the first 12 weeks in TRT1 (and up to Week 52), all participants were switched to ligelizumab 120 mg s.c. pre-filled syringe (PFS) Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab outside the clinic.

The second half of the treatment period (TRT2) was 52 weeks (from Week 52 to Week 104). Participants with UAS7>6 and <16 or with UAS7 ≥ 16 for whom the benefit-risk was deemed as positive by the investigator at Week 52 of TRT1 were transitioned to the TRT2 (ligelizumab 120 mg s.c. Q4W PFS) unless a decision to stop treatment was made based on a risk-benefit assessment. They were not allowed to discontinue H1- AH background medication.

Participants with UAS7 ≤ 6 at Week 52 of TRT1 entered the second (investigational treatment-free) observation period (OBS2) for up to 52 weeks and remained on the same H1-AH background medication they were taking in the preceding studies. Participants with UAS7 ≤ 6 at Week 52 of TRT1 who entered the second observation period (OBS2) and relapsed (UAS7 ≥ 16) were transitioned to the TRT2 and were also offered the opportunity to discontinue their H1-AH background medication (i.e. ligelizumab 120 mg s.c. q4w PFS monotherapy) after 12 weeks in TRT2. Participants who entered the OBS2 and did not relapse (UAS7<16) exited the study at the end of the OBS2 period.

Finally, participants who were in TRT2 entered the post-treatment follow-up period after treatment discontinuation, with duration of 12 weeks (for participants who did not complete a continuous 104-week treatment) or 52 weeks (for participants who completed the full 104-week treatment period without interruption). Participants who decided to remain on H1-AH background medication continued to use H1-AH background medication. Participants who decided to go off H1- AH background medication continued to remain off.

Conditions

Chronic Spontaneous Urticaria

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Ligelizumab 72 mg LIVI -ligelizumab 120 mg PFS

Participants received 72 mg of ligelizumab liquid in vial (LIVI) subcutaneously every 4 weeks for the first 12 weeks. Thereafter, participants received 120 mg of ligelizumab pre-filled syringe (PFS) subcutaneously every 4 weeks for up to 92 additional weeks (continuous or interrupted if the participant entered the observation period 2).

Group Type: EXPERIMENTAL

Ligelizumab

Intervention Type: DRUG

For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.

Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.

The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period.

Ligelizumab 120 mg LIVI -ligelizumab 120 mg PFS

Participants received 120 mg of ligelizumab liquid in vial (LIVI) subcutaneously every 4 weeks for the first 12 weeks. Thereafter, participants received 120 mg of ligelizumab pre-filled syringe (PFS) subcutaneously every 4 weeks for up to 92 additional weeks (continuous or interrupted if the participant entered the observation period 2).

Group Type: EXPERIMENTAL

Ligelizumab

Intervention Type: DRUG

For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.

Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.

The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period.

Interventions

Ligelizumab

For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.

Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.

The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period.

Intervention Type: DRUG

Other Intervention Names

QGE031

Eligibility Criteria

Inclusion Criteria

• Written informed consent
• Subjects who successfully completed all of the treatment period and the follow-up period in any of the following studies: CQGE031C2302 (NCT03580369), CQGE031C2303 (NCT03580356), CQGE031C2202 (NCT03437278) or CQGE031C1301 (NCT03907878)
• Male and female, adult and adolescent subjects ≥12 years of age
• Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedule

Exclusion Criteria

• Use of investigational drugs, other than those in use in the preceding studies, at the time of enrollment
• Use of omalizumab within 16 weeks of Screening
• History of hypersensitivity to the study drug ligelizumab or its components, or to drugs of similar chemical classes
• New onset or signs and symptoms of any form of chronic urticarias other than CSU during the preceding studies CQGE031C2302 (NCT03580369), CQGE031C2303 (NCT03580356) or CQGE031C2202 (NCT03437278).
• Diseases with possible symptoms of urticaria or angioedema
• Subjects with evidence of helminthic parasitic infection
• Documented history of anaphylaxis
• Pregnant or nursing (lactating) women

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Birmingham, Alabama, United States

Novartis Investigative Site

Gilbert, Arizona, United States

Novartis Investigative Site

Litchfield Park, Arizona, United States

Novartis Investigative Site

Scottsdale, Arizona, United States

Novartis Investigative Site

Little Rock, Arkansas, United States

Novartis Investigative Site

Bakersfield, California, United States

Novartis Investigative Site

Los Angeles, California, United States

Novartis Investigative Site

Redwood City, California, United States

Novartis Investigative Site

San Jose, California, United States

Novartis Investigative Site

Colorado Springs, Colorado, United States

Novartis Investigative Site

Denver, Colorado, United States

Novartis Investigative Site

Greenacres City, Florida, United States

Novartis Investigative Site

Sarasota, Florida, United States

Novartis Investigative Site

Tallahassee, Florida, United States

Novartis Investigative Site

Tampa, Florida, United States

Novartis Investigative Site

Boise, Idaho, United States

Novartis Investigative Site

Evansville, Indiana, United States

Novartis Investigative Site

Indianapolis, Indiana, United States

Novartis Investigative Site

Overland Park, Kansas, United States

Novartis Investigative Site

Bangor, Maine, United States

Novartis Investigative Site

Baltimore, Maryland, United States

Novartis Investigative Site

White Marsh, Maryland, United States

Novartis Investigative Site

Ypsilanti, Michigan, United States

Novartis Investigative Site

Minneapolis, Minnesota, United States

Novartis Investigative Site

Rochester, Minnesota, United States

Novartis Investigative Site

St Louis, Missouri, United States

Novartis Investigative Site

Missoula, Montana, United States

Novartis Investigative Site

Cincinnati, Ohio, United States

Novartis Investigative Site

Toledo, Ohio, United States

Novartis Investigative Site

Oklahoma City, Oklahoma, United States

Novartis Investigative Site

Tulsa, Oklahoma, United States

Novartis Investigative Site

Clackamas, Oregon, United States

Novartis Investigative Site

Medford, Oregon, United States

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Novartis Investigative Site

North Charleston, South Carolina, United States

Novartis Investigative Site

El Paso, Texas, United States

Novartis Investigative Site

San Antonio, Texas, United States

Novartis Investigative Site

Murray, Utah, United States

Novartis Investigative Site

Bellingham, Washington, United States

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

Ciudad Autonoma de Bs As, Buenos Aires, Argentina

Novartis Investigative Site

La Plata, Buenos Aires, Argentina

Novartis Investigative Site

Mendoza, Mendoza Province, Argentina

Novartis Investigative Site

Buenos Aires, Nueve De Julio, Argentina

Novartis Investigative Site

Santa Fe, Rosario, Argentina

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Novartis Investigative Site

Bahía Blanca, , Argentina

Novartis Investigative Site

Buenos Aires, , Argentina

Novartis Investigative Site

Buenos Aires, , Argentina

Novartis Investigative Site

CABA, , Argentina

Novartis Investigative Site

Capital Federal, , Argentina

Novartis Investigative Site

Salta, , Argentina

Novartis Investigative Site

Adelaide, South Australia, Australia

Novartis Investigative Site

East Melbourne, Victoria, Australia

Novartis Investigative Site

Parkville, Victoria, Australia

Novartis Investigative Site

Vienna, , Austria

Novartis Investigative Site

Jette, Brussels Capital, Belgium

Novartis Investigative Site

Ghent, , Belgium

Novartis Investigative Site

Leuven, , Belgium

Novartis Investigative Site

Loverval, , Belgium

Novartis Investigative Site

Salvador, Estado de Bahia, Brazil

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Novartis Investigative Site

Alphaville Barueri, São Paulo, Brazil

Novartis Investigative Site

Santo André, São Paulo, Brazil

Novartis Investigative Site

São José do Rio Preto, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

Pleven, , Bulgaria

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Varna, , Bulgaria

Novartis Investigative Site

Hamilton, Ontario, Canada

Novartis Investigative Site

Kingston, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Waterloo, Ontario, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Québec, Quebec, Canada

Novartis Investigative Site

Vitacura, Santiago Metropolitan, Chile

Novartis Investigative Site

Osorno, , Chile

Novartis Investigative Site

Santiago, , Chile

Novartis Investigative Site

Medellín, Antioquia, Colombia

Novartis Investigative Site

Zagreb, , Croatia

Novartis Investigative Site

Teplice, CZE, Czechia

Novartis Investigative Site

Prague, Prague 1, Czechia

Novartis Investigative Site

Olomouc, , Czechia

Novartis Investigative Site

Pilsen, , Czechia

Novartis Investigative Site

Copenhagen NV, , Denmark

Novartis Investigative Site

Tallinn, , Estonia

Novartis Investigative Site

Clermont-Ferrand, , France

Novartis Investigative Site

Nice, , France

Novartis Investigative Site

Pierre-Bénite, , France

Novartis Investigative Site

Rouen, , France

Novartis Investigative Site

Toulouse, , France

Novartis Investigative Site

Bad Bentheim, , Germany

Novartis Investigative Site

Berlin, , Germany

Novartis Investigative Site

Bochum, , Germany

Novartis Investigative Site

Dresden, , Germany

Novartis Investigative Site

Erlangen, , Germany

Novartis Investigative Site

Essen, , Germany

Novartis Investigative Site

Frankfurt, , Germany

Novartis Investigative Site

Freiburg im Breisgau, , Germany

Novartis Investigative Site

Göttingen, , Germany

Novartis Investigative Site

Halle, , Germany

Novartis Investigative Site

Hamburg, , Germany

Novartis Investigative Site

Hanover, , Germany

Novartis Investigative Site

Heidelberg, , Germany

Novartis Investigative Site

Jena, , Germany

Novartis Investigative Site

Langenau, , Germany

Novartis Investigative Site

Leipzig, , Germany

Novartis Investigative Site

Mainz, , Germany

Novartis Investigative Site

Marburg, , Germany

Novartis Investigative Site

Memmingen, , Germany

Novartis Investigative Site

München, , Germany

Novartis Investigative Site

München, , Germany

Novartis Investigative Site

Osnabrück, , Germany

Novartis Investigative Site

Stade, , Germany

Novartis Investigative Site

Stuttgart, , Germany

Novartis Investigative Site

Tübingen, , Germany

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Guatemala City, , Guatemala

Novartis Investigative Site

Guatemala City, , Guatemala

Novartis Investigative Site

Kecskemét, Bács-Kiskun county, Hungary

Novartis Investigative Site

Szeged, Csongrád megye, Hungary

Novartis Investigative Site

Debrecen, , Hungary

Novartis Investigative Site

Pécs, , Hungary

Novartis Investigative Site

Bangalore, Karnataka, India

Novartis Investigative Site

Belagavi, Karnataka, India

Novartis Investigative Site

Mangalore, Karnataka, India

Novartis Investigative Site

Nashik, Maharashtra, India

Novartis Investigative Site

Nashik, Maharashtra, India

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Novartis Investigative Site

New Delhi, , India

Novartis Investigative Site

Vijayawada, , India

Novartis Investigative Site

Haifa, , Israel

Novartis Investigative Site

Jerusalem, , Israel

Novartis Investigative Site

Kfar Saba, , Israel

Novartis Investigative Site

Ramat Gan, , Israel

Novartis Investigative Site

Rehovot, , Israel

Novartis Investigative Site

Cagliari, CA, Italy

Novartis Investigative Site

Florence, FI, Italy

Novartis Investigative Site

Rozzano, MI, Italy

Novartis Investigative Site

Siena, SI, Italy

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

Novartis Investigative Site

Ichikawa, Chiba, Japan

Novartis Investigative Site

Chikushino-shi, Fukuoka, Japan

Novartis Investigative Site

Hiroshima, Hiroshima, Japan

Novartis Investigative Site

Obihiro, Hokkaido, Japan

Novartis Investigative Site

Kobe, Hyōgo, Japan

Novartis Investigative Site

Nishinomiya, Hyōgo, Japan

Novartis Investigative Site

Kawasaki, Kanagawa, Japan

Novartis Investigative Site

Yokohama, Kanagawa, Japan

Novartis Investigative Site

Yokohama, Kanagawa, Japan

Novartis Investigative Site

Yokohama, Kanagawa, Japan

Novartis Investigative Site

Kamimashi-gun, Kumamoto, Japan

Novartis Investigative Site

Neyagawa, Osaka, Japan

Novartis Investigative Site

Sakai, Osaka, Japan

Novartis Investigative Site

Izumo, Shimane, Japan

Novartis Investigative Site

Itabashi-ku, Tokyo, Japan

Novartis Investigative Site

Machida, Tokyo, Japan

Novartis Investigative Site

Setagaya-ku, Tokyo, Japan

Novartis Investigative Site

Shinagawa Ku, Tokyo, Japan

Novartis Investigative Site

Fukuoka, , Japan

Novartis Investigative Site

Beirut, , Lebanon

Novartis Investigative Site

El Achrafiyé, , Lebanon

Novartis Investigative Site

Saida, , Lebanon

Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, Malaysia

Novartis Investigative Site

Ipoh, Perak, Malaysia

Novartis Investigative Site

George Town, Pulau Pinang, Malaysia

Novartis Investigative Site

Guadalajara, Jalisco, Mexico

Novartis Investigative Site

Villahermosa, Tabasco, Mexico

Novartis Investigative Site

Bergen op Zoom, , Netherlands

Novartis Investigative Site

Breda, , Netherlands

Novartis Investigative Site

Utrecht, , Netherlands

Novartis Investigative Site

Muscat, , Oman

Novartis Investigative Site

Miraflores, Lima region, Peru

Novartis Investigative Site

San Borja, Lima region, Peru

Novartis Investigative Site

City of Taguig, National Capital Region, Philippines

Novartis Investigative Site

Pasig, , Philippines

Novartis Investigative Site

Ksawerów, POL, Poland

Novartis Investigative Site

Gdansk, , Poland

Novartis Investigative Site

Gdansk, , Poland

Novartis Investigative Site

Krakow, , Poland

Novartis Investigative Site

Lodz, , Poland

Novartis Investigative Site

Rzeszów, , Poland

Novartis Investigative Site

Warsaw, , Poland

Novartis Investigative Site

Wroclaw, , Poland

Novartis Investigative Site

San Juan, , Puerto Rico

Novartis Investigative Site

Bucharest, District 2, Romania

Novartis Investigative Site

Brasov, , Romania

Novartis Investigative Site

Cluj-Napoca, , Romania

Novartis Investigative Site

Chelyabinsk, , Russia

Novartis Investigative Site

Kazan', , Russia

Novartis Investigative Site

Moscow, , Russia

Novartis Investigative Site

Moscow, , Russia

Novartis Investigative Site

Rostov-on-Don, , Russia

Novartis Investigative Site

Ryazan, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Saratov, , Russia

Novartis Investigative Site

Smolensk, , Russia

Novartis Investigative Site

Stavropol, , Russia

Novartis Investigative Site

Singapore, , Singapore

Novartis Investigative Site

Singapore, , Singapore

Novartis Investigative Site

Singapore, , Singapore

Novartis Investigative Site

Kežmarok, , Slovakia

Novartis Investigative Site

Komárno, , Slovakia

Novartis Investigative Site

Levice, , Slovakia

Novartis Investigative Site

Nové Zámky, , Slovakia

Novartis Investigative Site

Považská Bystrica, , Slovakia

Novartis Investigative Site

Svidník, , Slovakia

Novartis Investigative Site

Topoľčany, , Slovakia

Novartis Investigative Site

Žilina, , Slovakia

Novartis Investigative Site

Cape Town, Western Province, South Africa

Novartis Investigative Site

Cape Town, , South Africa

Novartis Investigative Site

Durban, , South Africa

Novartis Investigative Site

Daegu, Dalseo Gu, South Korea

Novartis Investigative Site

Wŏnju, Gangwon-do, South Korea

Novartis Investigative Site

Hwaseong-si, Gyeonggi-do, South Korea

Novartis Investigative Site

Suwon, Gyeonggi-do, South Korea

Novartis Investigative Site

Seoul, Korea, South Korea

Novartis Investigative Site

Seoul, Seocho Gu, South Korea

Novartis Investigative Site

Incheon, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Seville, Andalusia, Spain

Novartis Investigative Site

Esplugues de Llobregat, Barcelona, Spain

Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, Spain

Novartis Investigative Site

Bilbao, Basque Country, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Alcorcón, Madrid, Spain

Novartis Investigative Site

Pozuelo de Alarcón, Madrid, Spain

Novartis Investigative Site

Pamplona, Navarre, Spain

Novartis Investigative Site

San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain

Novartis Investigative Site

Alicante, Valencia, Spain

Novartis Investigative Site

Valencia, Valencia, Spain

Novartis Investigative Site

Barcelona, , Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Valencia, , Spain

Novartis Investigative Site

Taoyuan District, Taiwan, Taiwan

Novartis Investigative Site

Taichung, , Taiwan

Novartis Investigative Site

Taipei, , Taiwan

Novartis Investigative Site

Bangkoknoi, Bangkok, Thailand

Novartis Investigative Site

Bangkok, Phayathai, Thailand

Novartis Investigative Site

Bangkok, , Thailand

Novartis Investigative Site

Sfax, Tunusia, Tunisia

Novartis Investigative Site

Sousse, , Tunisia

Novartis Investigative Site

Tunis, , Tunisia

Novartis Investigative Site

Istanbul, Pendik, Turkey (Türkiye)

Novartis Investigative Site

Istanbul, TUR, Turkey (Türkiye)

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Novartis Investigative Site

Aydin, , Turkey (Türkiye)

Novartis Investigative Site

Denizli, , Turkey (Türkiye)

Novartis Investigative Site

Izmir, , Turkey (Türkiye)

Novartis Investigative Site

Okmeydanı, , Turkey (Türkiye)

Novartis Investigative Site

Samsun, , Turkey (Türkiye)

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

Hanoi, , Vietnam

Novartis Investigative Site

Ho Chi Minh City, , Vietnam

Countries

United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czechia; Denmark; Estonia; France; Germany; Greece; Guatemala; Hungary; India; Israel; Italy; Japan; Lebanon; Malaysia; Mexico; Netherlands; Oman; Peru; Philippines; Poland; Puerto Rico; Romania; Russia; Singapore; Slovakia; South Africa; South Korea; Spain; Taiwan; Thailand; Tunisia; Turkey (Türkiye); United Kingdom; Vietnam

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1561

Patient Lay Trial Summary

Other Identifiers

2019-001792-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CQGE031C2302E1

Identifier Type: -

Identifier Source: org_study_id